Medical Complications in Pregnancy Flashcards
1
Q
Types of hypertension in pregnancy
A
- Chronic Hypertension
- Pregnancy Induced Hypertension
- Preeclampsia
- Eclampsia
- HELLP syndrome
2
Q
incidence of HTN in pregnancy
A
- Hypertensive disorders occur in approximately 12% - 22% of pregnancies
- Hypertensive diseases responsible for approximately 20% of maternal deaths in the US
3
Q
chronic HTN
A
- Chronic hypertension (HTN) defined hypertension present before 20th week of pregnancy or hypertension present before pregnancy
- Mild hypertension – systolic of > 140-180 mmHg or diastolic > 90-100 mmHg or both
- Severe hypertension - systolic of > 180 mmHg or diastolic > 100 mmHg
- Major risk factor with chronic HTN is development of preeclampsia or eclampsia later in pregnancy
4
Q
Gestational Hypertension/pregnancy indued HTN
A
- HTN that develops after 20 weeks of gestation in the absence of proteinuria and returns to normal postpartum
- Develops in 5-10% of pregnancies that go beyond first trimester
- 30% incidence in multiple gestations
- Approximately 25% of women with gestational HTN develop superimposed preeclampsia or eclampsia
- Difficult to distinguish if woman is seen late in pregnancy with elevated blood pressure à assume preeclampsia and treat accordingly
5
Q
Preeclampsia
A
- Preeclampsia - new onset of hypertension and either proteinuria or end-organ dysfunction after 20 weeks of gestation in a previously normotensive woman
- Severe hypertension and signs/symptoms of end-organ injury are considered the severe spectrum of the disease
- Recent revisions to diagnosis -American College of Obstetricians and Gynecologists revisions (2013)
- Removed proteinuria as an essential criterion for diagnosis of preeclampsia
- Removed massive proteinuria (5 grams/24 hours) and fetal growth restriction as possible features of severe disease
- Oliguria was removed as a characteristic of severe disease.
- BURDEN OF DISEASE - Women with preeclampsia are at an increased risk for life-threatening events: placental abruption, ARF, cerebral hemorrhage, hepatic failure or rupture, pulmonary edema, DIC, and progression to eclampsia.
- Worldwide, 10 -15% of direct maternal deaths (resulting from obstetric complications of pregnancy) are associated with preeclampsia/eclampsia.
- In the United States, preeclampsia/eclampsia is one of four leading causes of maternal death. 303,000 women died of maternal causes in 2015.
- Morbidity and mortality are also increased for the fetus/neonate
6
Q
Maternal Mortality
A
- Defined as the death of a mother from pregnancy related complications while she is carrying or within 42 days after birth.
- In the US, rates soared by 27%, from 19 per 100,000 to 24 per 100,000 between 2000 and 2014.
- That’s more than 3 times the rate of the UK, and about 8 times the rate of Netherlands, Norway, and Sweden!
- The US National Center for Health Statistics has not even published an official maternal mortality rate since 2007–that’s how low priority this issue is
- More women in labor or brand-new mothers die here then in any other high income country
- One of the United Nations Millennium Development Goals focused on driving down the maternal mortality rate which led to efforts in almost every country to save mothers lives, which were largely successful: Global maternity mortality rate dropped by 44% worldwide between 1990 and 2015, and by 48% and developed countries.
- The US was one of only 13 countries, including North Korea Zimbabwe, that saw its maternal death rate increase since 1990.
7
Q
Preeclampsia with severe features
A
- Blood pressure of > 160mm Hg systolic or > 110 mmHg diastolic
- Progressive renal insufficiency (serum creatinine >1.1 mg/dL or doubling of serum creatinine concentration in the absence of other renal disease)
- Cerebral or visual disturbances (headache and scotomata)
- Pulmonary edema or cyanosis
- Epigastric or RUQ pain
- Evidence of hepatic dysfunction (transaminases doubled)
- Thrombocytopenia (<100,000)
8
Q
eclampsia
A
- Presence of convulsions (grand mal seizures) in a woman with preeclampsia not explained by neurological disorder
- Occurs in 0.5% of patients with preeclampsia
- Most cases occur within 24 hours of delivery but approximately 3% of cases diagnosed between 2 and 10 days postpartum
9
Q
Risk factors - preeclampsia
A
- Nulliparity
- Age <20 y.o., >35 y.o.
- New paternity/partner related factors
- Family history of preeclampsia
- Chronic renal disease, chronic HTN
- Prolonged interpregnancy interval
- Antiphospholipid syndrome
- Diabetes mellitus
- Multi-fetal gestation
- High BMI
- Black race
- Connective tissue disorders (RA, SLE)
- Smoking DECREASES risk, ASA for high risk?
10
Q
pathophysiology of preeclampsia - disease of theories
A
- Likely involves both maternal and fetal/placental factors.
- Abnormalities in the development of placental vasculature early in pregnancy may result in relative placental underperfusion/hypoxia/ischemia, => leads to release of antiangiogenic factors into the maternal circulation that alter maternal systemic endothelial function => HTN and other manifestations of the disease.
- Placental tissue is necessary for development of the disease, but the fetus is not
- Preeclampsia is always cured after delivery of the placenta
-
Abnormal remodeling of spiral arteries – results in placental hypoperfusion, hypoxia and ischemia
- This releases a variety of factors into the maternal bloodstream that alter maternal endothelial cell function and lead to the characteristic systemic signs and symptoms of preeclampsia
- Immunologic factors
- Immunologic abnormalities, similar to those observed in organ rejection graft versus host disease, have been observed in preeclamptic women
- Increased sensitivity to angiotensin II
- Genetic factors - Although most cases of preeclampsia are sporadic, genetic factors are thought to play a role in disease susceptibility.
- Immunologic factors - Nulliparous women/women who change partners between pregnancies, have long interpregnancy intervals, use barrier contraception, and conceive via intracytoplasmic sperm injection have less exposure to paternal antigens and higher risks of developing preeclampsia.
- Genetic factors - Primigravid women with a FH of preeclampsia (affected mother or sister) have a 2-5x higher risk of the disease than primigravid women with no such history.
- Risk of preeclampsia is increased more than 7x in women who have had preeclampsia in a previous pregnancy
- The spouses of men who were the product of a pregnancy complicated by preeclampsia are more likely to develop preeclampsia than spouses of men without this history.
- Systemic endothelial dysfunction
- Laboratory evidence supporting generalized endothelial dysfunction in preeclamptic women includes :
- Increased concentrations of circulating cellular fibronectin, factor VIII antigen, and thrombomodulin.
- Impaired flow-mediated vasodilation and impaired acetylcholine mediated vasorelaxation.
- Decreased production of endothelial-derived vasodilators (nitric oxide and prostacyclin), and increased production of vasoconstrictors (endothelins and thromboxanes).
- Systemic endothelial dysfunction - HTN results from disturbed endothelial control of vascular tone, proteinuria and edema are caused by increased vascular permeability, and coagulopathy is the result of abnormal endothelial expression of procoagulants. Headache, seizures, visual symptoms, epigastric pain, and IUGR are the sequelae of endothelial dysfunction in the vasculature of target organs, such as the brain, liver, kidney, and placenta.
11
Q
evaluation of preeclampsia
A
- Detailed H&P - hx of HTN, previous preeclampsia
- Review of obstetric records if applicable
- Signs/symptoms include: visual disturbances, severe/persistent HA, RUQ pain, Hx of LOC/seizures, dizziness
- BP - Proper position important/cuff size, BP tends to decline in 2nd trimester
- Weight - rapid weight gain (2 lbs/week)
- Normal weight gain is 1 lb per week
- Edema - unresponsive to rest in supine position especially in upper extremities, sacral region and face
- DTRs - hyperreflexia or clonus at ankle worrisome
12
Q
Laboratory evaluation of preeclampsia
A
- Maternal studies:
- CBC – rising HCT signals worsening vasoconstriction and intravascular volume or hemolysis
- Platelet count – thrombocytopenia
- Coagulation profile (PT, PTT) – coagulopathy
- LFTs – hepatocellular dysfunction
- Serum creatinine – decreasing renal function
- Uric acid
- 24 hour urine
- Creatinine clearance
- Total urinary protein
13
Q
fetal studies for preeclampsia
A
- Ultrasound exam for fetal weight and growth, and amniotic fluid volume
- NST and/or biophysical profile - indirect assessment of placental status
14
Q
biophysical profile
A
- The biophysical profile (BPP) has 5 components: 4 ultrasound (US) assessments and a nonstress test (NST).
- The NST evaluates fetal heart rate and response to fetal movement. The five discrete biophysical variables:
- Fetal movement
- Fetal tone
- Fetal breathing
- Amniotic fluid volume
- Fetal Heart Rate
- Each assessment is graded either 0 or 2 points, totalling 0 to 10. ( 8 or 10 is generally considered reassuring)
- A BPP normally is not performed before the second half of a pregnancy, since fetal breathing movements do not occur in the first half.
- The presence of these biophysical variables implies absence of significant central nervous system hypoxemia/acidemia at the time of testing. By comparison, a compromised fetus typically exhibits loss of accelerations of the fetal heart rate (FHR), decreased body movement and breathing, hypotonia, and, less acutely, decreased amniotic fluid volume.
15
Q
management of chronic hypertension
A
- Goal of management of hypertension in pregnancy is to balance the management of both fetus and mother and to optimize outcome for each…
- Close monitoring of maternal blood pressure
- Watching for superimposition of preeclampsia or eclampsia
- Following fetus for appropriate growth and fetal well - being
- Antihypertensive medications for women with chronic hypertension generally not given unless systolic pressure is 150 - 160 mm Hg or diastolic pressure 100 - 110 mm Hg
- Purpose of medication is to reduce likelihood of maternal stroke
- Methyldopa, combined alpha - and beta - blocker (i.e. labetalol) and calcium channel blockers (i.e. nifedipine)